These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21894796)

  • 21. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents.
    Frommeyer G; Fischer C; Ellermann C; Dechering DG; Kochhäuser S; Lange PS; Wasmer K; Fehr M; Eckardt L
    Cardiovasc Toxicol; 2018 Feb; 18(1):84-90. PubMed ID: 28612303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of sudden cardiac death following Domperidone self-medication.
    Fais P; Vermiglio E; Laposata C; Lockwood R; Gottardo R; De Leo D
    Forensic Sci Int; 2015 Sep; 254():e1-3. PubMed ID: 26119456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
    Valentin JP; Hoffmann P; De Clerck F; Hammond TG; Hondeghem L
    J Pharmacol Toxicol Methods; 2004; 49(3):171-81. PubMed ID: 15172013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual role of domperidone in gastroparesis and lactation.
    Phan H; DeReese A; Day AJ; Carvalho M
    Int J Pharm Compd; 2014; 18(3):203-7. PubMed ID: 25306766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological management of low milk supply with domperidone: separating fact from fiction.
    Grzeskowiak LE; Amir LH
    Med J Aust; 2014 Sep; 201(5):257-8. PubMed ID: 25163368
    [No Abstract]   [Full Text] [Related]  

  • 26. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?
    Lertxundi U; Domingo-Echaburu S; Soraluce A; García M; Ruiz-Osante B; Aguirre C
    Curr Drug Saf; 2013 Feb; 8(1):63-8. PubMed ID: 23656449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.
    Bacchi S; Chim I; Kramer P; Postuma RB
    J Parkinsons Dis; 2017; 7(4):603-617. PubMed ID: 29103053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cardiac adverse effects of domperidone in adult patients: a systematic review].
    Marzi M; Weitz D; Avila A; Molina G; Caraballo L; Piskulic L
    Rev Med Chil; 2015 Jan; 143(1):14-21. PubMed ID: 25860264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis.
    Leelakanok N; Holcombe A; Schweizer ML
    Clin Drug Investig; 2016 Feb; 36(2):97-107. PubMed ID: 26649742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. French journal calls for domperidone to be withdrawn.
    Benkimoun P
    BMJ; 2014 Feb; 348():g1722. PubMed ID: 24566259
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study.
    Arana A; Johannes CB; McQuay LJ; Varas-Lorenzo C; Fife D; Rothman KJ
    Drug Saf; 2015 Dec; 38(12):1187-99. PubMed ID: 26350642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone.
    Frommeyer G; Fischer C; Ellermann C; Lange PS; Dechering DG; Kochhäuser S; Fehr M; Eckardt L
    Cardiovasc Toxicol; 2017 Oct; 17(4):451-457. PubMed ID: 28185059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta-analysis of observational studies.
    Ou LB; Moriello C; Douros A; Filion KB
    Br J Clin Pharmacol; 2021 Oct; 87(10):3649-3658. PubMed ID: 33439512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.
    Renoux C; Dell'Aniello S; Khairy P; Marras C; Bugden S; Turin TC; Blais L; Tamim H; Evans C; Steele R; Dormuth C; Ernst P;
    Br J Clin Pharmacol; 2016 Aug; 82(2):461-72. PubMed ID: 27062307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Domperidone and sudden death.
    Prescrire Int; 2006 Dec; 15(86):226. PubMed ID: 17167933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart.
    Guérard NC; Traebert M; Suter W; Dumotier BM
    J Pharmacol Toxicol Methods; 2008; 58(1):32-40. PubMed ID: 18582585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Making a case for domperidone in the treatment of gastrointestinal motility disorders.
    Ahmad N; Keith-Ferris J; Gooden E; Abell T
    Curr Opin Pharmacol; 2006 Dec; 6(6):571-6. PubMed ID: 16997628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Domperidone: a peripherally acting dopamine2-receptor antagonist.
    Barone JA
    Ann Pharmacother; 1999 Apr; 33(4):429-40. PubMed ID: 10332535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.